Using the data from TCGA, we found that SLA2 expression was significantly elevated in 19 of 33 cancer types, including kidney renal papillary cell carcinoma (KIRP), kidney renal clear cell carcinoma (KIRC), stomach adenocarcinoma (STAD), among others (Fig. 1A). This evidence concerns the gene SLA2 and gastric adenocarcinoma.